This article is more than 5 years old. Information may no longer be current.
Autologous chondrocyte implantation on biphasic scaffold improved pain and function
Click Here to Manage Email Alerts
CHICAGO — Significant medium- to long-term improvements in pain and function were demonstrated among patients who underwent autologous chondrocyte implantation on a biphasic scaffold, according to a presenter here.
“This was a prospective, multicenter trial with characterized chondrocytes on a biphasic scaffold,” Jason L. Koh, MD, said in his presentation at the International Cartilage Repair Society Annual Meeting. “This was a simple, reproducible technique with good confidence intervals in terms of outcomes from a number of different of institutions, with significant medium- to long-term improvement. The outcomes did remain stable or actually improved over time.”
Jason L. Koh
Koh and colleagues recorded demographics, history and examination information, as well as IKDC scores, on 182 patients from seven participating centers who underwent autologous chondrocyte implantation using the biphasic collagen scaffold.
Results showed 50.1% of defects were localized degenerative, 21% were traumatic and 21% were osteochondrosis dissecans.
“The majority of [the defects] were located on the medial femoral condyle,” Koh said. “The remainder were primarily on the lateral femoral condyle, and an isolated few were on the trochlea.”
Koh noted consistent improvement in IKDC scores, as well as improvement in degenerative lesions from baseline to 5 years.
“What we found was that there were significant improvements in the IKDC score in the first year, and that improvements continued to go on up to year 2,” Koh said. “There was still substantial improvement out to year 5.”
Overall, 83.3% of patients were classified as responders, according to study results. Elevated expressions of interleukin-1, fms-related tyrosine kinase-1 and decreased expressions of collagen type 2 increased failure rates. – by Casey Tingle
Reference:
Koh J, et al. Prospective longitudinal evaluation of 182 patients with autologous chondrocyte implantation on a novel biphasic collagen scaffold. Presented at: International Cartilage Repair Society Annual Meeting. May 8-11, 2015; Chicago.
Disclosure: Koh is a paid consultant for Aesculap/B. Braun, Arthrex and Aperion; has stock or stock options with Aperion; and is a board or committee member for the American Orthopaedic Society for Sports Medicine, the Arthroscopy Association of North America, the Illinois Association of Orthopaedic Surgeons and the Patellofemoral Foundation.